Real-time Estimate
Cboe BZX
03:55:56 2024-05-28 pm EDT
|
5-day change
|
1st Jan Change
|
268.8
USD
|
-1.50%
|
|
-1.97%
|
+22.68%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,865
|
6,746
|
9,731
|
12,674
|
10,333
|
12,107
|
-
|
-
|
Enterprise Value (EV)
1 |
3,977
|
5,711
|
9,637
|
12,513
|
8,039
|
9,918
|
8,158
|
6,872
|
P/E ratio
|
-36.9
x
|
13.2
x
|
21.5
x
|
18.5
x
|
11.1
x
|
11.2
x
|
10.2
x
|
10.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.67
x
|
4.55
x
|
5.77
x
|
6.55
x
|
4.44
x
|
4.43
x
|
4.1
x
|
3.86
x
|
EV / Revenue
|
2.74
x
|
3.85
x
|
5.72
x
|
6.46
x
|
3.45
x
|
3.63
x
|
2.76
x
|
2.19
x
|
EV / EBITDA
|
-28.1
x
|
8.87
x
|
15.9
x
|
12.1
x
|
6.49
x
|
7
x
|
5.55
x
|
4.61
x
|
EV / FCF
|
-13.7
x
|
8.2
x
|
20.2
x
|
18.9
x
|
10.8
x
|
9.24
x
|
7.15
x
|
5.16
x
|
FCF Yield
|
-7.3%
|
12.2%
|
4.95%
|
5.3%
|
9.3%
|
10.8%
|
14%
|
19.4%
|
Price to Book
|
1.39
x
|
1.99
x
|
2.67
x
|
2.67
x
|
1.73
x
|
1.77
x
|
1.51
x
|
1.32
x
|
Nbr of stocks (in thousands)
|
43,881
|
44,441
|
45,037
|
45,577
|
46,994
|
44,366
|
-
|
-
|
Reference price
2 |
88.08
|
151.8
|
216.1
|
278.1
|
219.9
|
272.9
|
272.9
|
272.9
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/24/22
|
2/22/23
|
2/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,449
|
1,483
|
1,686
|
1,936
|
2,328
|
2,734
|
2,954
|
3,139
|
EBITDA
1 |
-141.7
|
643.5
|
605.8
|
1,031
|
1,238
|
1,418
|
1,471
|
1,490
|
EBIT
1 |
-187.6
|
593.6
|
555.9
|
979.7
|
1,185
|
1,411
|
1,547
|
1,574
|
Operating Margin
|
-12.95%
|
40.02%
|
32.98%
|
50.6%
|
50.91%
|
51.61%
|
52.37%
|
50.13%
|
Earnings before Tax (EBT)
1 |
-165
|
638.9
|
593.9
|
950.6
|
1,274
|
1,536
|
1,691
|
1,719
|
Net income
1 |
-104.5
|
514.8
|
475.8
|
727.3
|
984.8
|
1,185
|
1,288
|
1,305
|
Net margin
|
-7.21%
|
34.71%
|
28.23%
|
37.56%
|
42.31%
|
43.36%
|
43.59%
|
41.58%
|
EPS
2 |
-2.390
|
11.54
|
10.06
|
15.00
|
19.81
|
24.47
|
26.64
|
26.78
|
Free Cash Flow
1 |
-290.3
|
696.4
|
477.4
|
663.7
|
747.6
|
1,073
|
1,141
|
1,331
|
FCF margin
|
-20.04%
|
46.95%
|
28.32%
|
34.28%
|
32.12%
|
39.24%
|
38.62%
|
42.4%
|
FCF Conversion (EBITDA)
|
-
|
108.22%
|
78.8%
|
64.37%
|
60.38%
|
75.68%
|
77.57%
|
89.33%
|
FCF Conversion (Net income)
|
-
|
135.28%
|
100.34%
|
91.26%
|
75.91%
|
90.51%
|
88.6%
|
101.98%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/24/22
|
2/22/23
|
2/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
415.2
|
461.9
|
466.9
|
516
|
491.5
|
506.9
|
596.5
|
609.4
|
614.7
|
677.7
|
684.3
|
700.3
|
696.9
|
795.3
|
840.8
|
EBITDA
|
182.4
|
300.5
|
214.5
|
327.2
|
188.8
|
297.7
|
326.3
|
340.3
|
273.8
|
371.3
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
169.8
|
288
|
201.8
|
314.3
|
175.6
|
284.4
|
313.4
|
327
|
260.1
|
356.3
|
366
|
372.2
|
343.7
|
502.5
|
503.9
|
Operating Margin
|
40.9%
|
62.35%
|
43.22%
|
60.91%
|
35.73%
|
56.11%
|
52.54%
|
53.66%
|
42.31%
|
52.57%
|
53.49%
|
53.16%
|
49.32%
|
63.18%
|
59.93%
|
Earnings before Tax (EBT)
1 |
140.5
|
308.7
|
150.6
|
312.5
|
178.8
|
291.9
|
335.2
|
351.8
|
295.4
|
398.6
|
401.5
|
407.9
|
351.8
|
545.2
|
547.2
|
Net income
1 |
112.2
|
239.9
|
116
|
239.3
|
132.1
|
240.9
|
259.2
|
267.6
|
217.1
|
306.6
|
309.8
|
315.2
|
281.2
|
430.7
|
432.3
|
Net margin
|
27.02%
|
51.94%
|
24.84%
|
46.38%
|
26.88%
|
47.52%
|
43.45%
|
43.91%
|
35.32%
|
45.24%
|
45.27%
|
45.02%
|
40.35%
|
54.16%
|
51.41%
|
EPS
2 |
2.350
|
5.030
|
2.410
|
4.910
|
2.670
|
4.860
|
5.240
|
5.380
|
4.360
|
6.170
|
6.258
|
6.505
|
5.796
|
9.180
|
9.210
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/4/22
|
8/3/22
|
11/2/22
|
2/22/23
|
5/3/23
|
8/2/23
|
11/1/23
|
2/21/24
|
5/1/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
112
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
1,035
|
94.8
|
161
|
2,294
|
2,189
|
3,948
|
5,235
|
Leverage (Debt/EBITDA)
|
-0.7876
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-290
|
696
|
477
|
664
|
748
|
1,073
|
1,141
|
1,331
|
ROE (net income / shareholders' equity)
|
-3.75%
|
16.7%
|
12.9%
|
16.6%
|
18.3%
|
17.6%
|
15.7%
|
13.1%
|
ROA (Net income/ Total Assets)
|
15.6%
|
12.1%
|
9.85%
|
13%
|
14.9%
|
15.2%
|
14.3%
|
12.6%
|
Assets
1 |
-671.4
|
4,264
|
4,832
|
5,607
|
6,606
|
7,796
|
9,026
|
10,381
|
Book Value Per Share
2 |
63.40
|
76.40
|
81.00
|
104.0
|
127.0
|
154.0
|
181.0
|
206.0
|
Cash Flow per Share
2 |
-4.720
|
16.90
|
12.60
|
16.50
|
19.70
|
25.80
|
25.60
|
28.70
|
Capex
1 |
83.7
|
59.3
|
121
|
139
|
230
|
170
|
250
|
204
|
Capex / Sales
|
5.78%
|
4%
|
7.17%
|
7.17%
|
9.9%
|
6.23%
|
8.48%
|
6.51%
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/24/22
|
2/22/23
|
2/21/24
|
-
|
-
|
-
|
Last Close Price
272.9
USD Average target price
294.2
USD Spread / Average Target +7.80% Consensus |
1st Jan change
|
Capi.
|
---|
| +24.10% | 12.11B | | +67.53% | 63.85B | | -0.77% | 41.83B | | +44.98% | 40.47B | | -10.87% | 27.17B | | +13.30% | 26.52B | | -22.79% | 18.69B | | +4.70% | 12.73B | | +27.41% | 12.07B | | -8.12% | 11.19B |
Other Biotechnology & Medical Research
|